Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132938 · ClinicalTrials.gov registry record · Phase 4
PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 5,660
- Enrollment target
NCT00132938 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 5,660 participants.
The verdict
NCT00132938, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5,660 participants
- Enrollment target
Study Summary
Primary Objective: * The primary objective of the study is to demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in the reduction of Streptococcus pneumoniae (Sp) strains resistant to beta-lactams or macrolides at the Test of Cure (TOC) visit in the sputum of patients with Sp detected at the start of the study (Visit 1). Secondary Objectives: The secondary objectives of the study are: * To demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in achieving clinical cure and Sp eradication success at the Test of Cure visit in patients with Sp detected in sputum specimen at the start of the study (Visit 1); * To compare the clinical cure rates achieved by each treatment group in the penicillin or erythromycin resistant Sp (PERSp) population with the cure rates in the sensitive Sp (SSp) population at the End of Therapy (EOT) and Test of Cure visits; * To compare the effect of telithromycin, azithromycin and cefuroxime axetil at the End of Therapy visit on the presence of Streptococcus pneumoniae strains resistant to beta-lactams or macrolides in the sputum of patients with Sp detected at the start of the study (Visit 1); * To compare the clinical efficacy at the End of Therapy visit and safety at the Test of Cure visit of telithromycin, azithromycin and cefuroxime axetil in the "global" randomized population.
Interventions
- DRUG telithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,660 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00132938
The ClinicalTrials.gov registry entry for NCT00132938 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5,660 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which telithromycin is the first listed.
NCT00132938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00132938 about?
NCT00132938 is a clinical study titled "PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis". Primary Objective: * The primary objective of the study is to demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in the reduction of Streptococcus pneumoniae (Sp) strains resistant to beta-lactams or macrolides at the Test of Cure (TOC) visit in the sputum of ...
What is the current status of trial NCT00132938?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5,660 participants. The study started on 2004-01. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00132938?
The interventions under investigation include: telithromycin (DRUG).
Who is sponsoring clinical trial NCT00132938?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.